HIV pre-exposure prophylaxis (PrEP)

PrEP is a highly effective strategy that involves an HIV-negative person taking HIV medications on an ongoing basis to reduce the risk of HIV infection. When PrEP is taken as prescribed, HIV transmission is very rare.

Resources

Filter By

Filter By

Research summary

tu-ta-book-img

In context – long-acting cabotegravir for HIV prevention

Trends in HIV PrEP use in nine Canadian provinces

Trends in HIV pre-exposure prophylaxis [HIV-PrEP] use in 9 Canadian provinces, 2019–2022

Research summary

Awareness, accessibility and uptake of pre-exposure prophylaxis (PrEP) among cisgender and transgender women at risk of HIV infection

Research summary

CATIE News 08032023

Ottawa study links use of PrEP to sustained decrease in new HIV cases

Research summary

CATIE News 07072023

Some views on injectable long-acting HIV pre-exposure prophylaxis (PrEP)

Research summary

PrEP ACB evidence brief img

PrEP navigation for Black/African American men who have sex with men

Research summary

PrEP use among trans people

What are the barriers and facilitators to HIV PrEP use among transgender people?

PrEP options

Research summary

CATIE News10252022

A large study of HIV pre-exposure prophylaxis finds no new cases of HIV with daily dosing

Research summary

CATIE News 10142022

Can long-acting pre-exposure prophylaxis have a big impact on HIV in the U.S.?

Cross-boundary PrEP collaboration: A model to emulate

Research summary

PiF Injectable PrEP

Worth a shot: Injectable PrEP for HIV prevention